News | July 23, 2025
Lonza reports 19% growth in sales in H1
Upgrades 2025 full-year CDMO sales and margin outlook
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
